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Abstract 
Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are 
required to treat these difficult diseases. Here we present a durable complete remission of a 
relapsed glioblastoma that has achieved a complete radiologic response with the 
combination of cetuximab and bevacizumab, in a third-line setting, that has offered a 
progression-free survival of 20 months. We consider here both potential mechanisms for the 
explanation of this result. First, the potential target of the cancer stem cells (CSCs) with 
these two antibodies, and second, the potential recruitment of the immune system to 
directly pursue the CSCs. 
 
Introduction 
Human brain tumors, both in pediatric cases and in adults, are a significant cause of 
morbidity and mortality. These tumors remain difficult to cure despite advances in 
surgery and adjuvant therapy techniques. Median survival in patients with 
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glioblastoma is approximately 12 months after surgery and adjuvant radiotherapy [1]. 
The role of chemotherapy in gliomas after relapse is unclear [2–4]. There are no 
documented benefits from the use of chemotherapy on these fatal tumors [5, 6]. 
However, previously published reports on the use of irinotecan and bevacizumab in 
patients with recurrent supratentorial malignant gliomas showed that these 
chemotherapies led to occasional radiographic responses with marginal improvement 
in progression-free survival [7–9]. 
Accumulating evidence demonstrates that malignant tumors contain cancer stem 
cells (CSCs) [10, 11], and these CSCs constitute a minor fraction of a given tumor. CSCs 
are capable of self-renewal, potent differentiation, exclusive tumorigenicity and drug 
resistance [12, 13]. The CSC hypothesis claims that, despite rigorous therapy, clinical 
relapse of tumors is inevitable as long as CSCs remain in the host [13]. This has been 
supported by observations in models of breast cancer [11], acute myeloid leukemia [14, 
15], and brain tumors [16], where isolated CSCs initiated new tumors when injected 
into experimental animals. 
One of the important issues for CSCs in gliomas is whether they contribute to the 
process of neovascularization, which includes angiogenesis and vasculogenesis. This is 
because stem cells produce higher levels of vascular endothelial growth factor (VEGF), 
which is inhibited by the VEGF-neutralizing antibody, bevacizumab [17]. Epidermal 
growth factor receptor (EGFR) has also been reported to be important to glioma CSCs, 
and it has been implicated in glioma aggressiveness, treatment unresponsiveness, and 
shortened survival [18]. 
In this paper, we report our experience with bevacizumab and cetuximab in an adult 
patient with progressive brainstem glioma. 
Case Report 
We reviewed the medical record of a patient from the Hospital de Denia – Marina Salud. The 
patient, a man, born in 1969, presented in March 2007 with progressive headaches, dizziness and 
dysgeusia. Magnetic resonance imaging (MRI) with contrast enhancement in a 5 × 5 × 5 cm ring 
demonstrated a right temporal mass of a cystic nature along with edema (fig. 1). 
Total removal of the tumor was performed on March 3, 2007, and the tumor was histologically 
proven to be a glioblastoma multiforme (GBM). The patient underwent standard treatments of 
adjuvant radiotherapy (60 Gy in 6 weeks) and adjuvant chemotherapy with administration of 
temozolomide, first administered concomitantly with radiotherapy (75 mg/m2/day), then 
administered sequentially (150 mg/m2/day for 5 days in each cycle of 28 days, for 6 cycles). 
MRI follow-up at 8 months after resection revealed suspicious signs of a local relapse in the 
surgical bed without areas of restricted diffusion. The hypometabolic lesion was followed until 
September 2008, when the patient suffered hemiparesis in the upper and lower extremities on the left 
side. MRI scans demonstrated new contrast-enhancing areas of an infiltrative tumor in the right 
temporal mass and corpus callosum (fig. 2). 
The patient was then started on intravenous irinotecan administered once every 2 weeks for 3 
cycles, but he did not exhibit any improvement. At this point, the patient came to our hospital for a 
second opinion. Because there is not a defined treatment for recurrent stages of glioblastoma, we 
discussed the option of using bevacizumab. Bevacizumab, either alone or in combination with 
chemotherapy, extends progression-free survival and has a steroid-sparing effect in glioblastoma 
patients relative to historical controls [7, 9, 19]. The patient refused to continue with irinotecan in any 
of the potential drug combinations. 
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After weighing the options and considering the potential dependence of CSCs on VEGF and EGFR, 
we recommended treatment with a combination of 500 mg/m2 cetuximab and 10 mg/kg bevacizumab 
every two weeks. During administration of bevacizumab and cetuximab, the patient did not suffer 
from any relevant adverse events due to the drugs. The major side effects noted were a grade 2 
acneiform skin reaction and dermatitis. The patient showed objective clinical improvement of his 
symptoms after only two cycles (fig. 3). 
The patient continued to show dramatic clinical improvement. Interval MRIs showed continuing 
decreases in the degree of contrast enhancement (fig. 4), and the patient was considered to be in 
complete radiological remission as of February 2011, when radiological relapse was documented, for 
a total of 20 months of progression-free survival (fig. 5). 
Discussion 
GBM is a very aggressive primary brain tumor resulting in a short life expectancy for 
patients after diagnosis and with a grim prognosis despite maximal treatment [20]. The 
role of conventional chemotherapy in the treatment of diffusely infiltrative gliomas 
remains unclear. Furthermore, the effectiveness of chemotherapy after relapse is 
uncertain. It has been suggested that tumorigenicity and resistance to therapy might 
not be a feature of all cells in the bulk tumor mass, but rather a feature of a select 
population of cells with a stem-like phenotype [21], the CSCs. This select population of 
stem-like cells from human GBMs displayed potential pro-angiogenic activity, adhesion 
molecule expression and chemoresistance, all features likely to contribute to glioma 
relapse and progression. Based on these reasons, we used a combination of 
bevacizumab and cetuximab to directly target CSCs. Therefore, clinical improvement in 
our patient following bevacizumab and cetuximab combined therapy could be 
attributable on one side to a direct effect of both drugs on the tumor by respectively 
neutralizing the excess of VEGF secretion and by blocking the binding of EGF and other 
ligands to EGFR as well as by promoting downregulation of the receptor, mainly in the 
CSC subpopulation. 
On the other side an additional immunomodulatory effect carried out by a 
synergistic action of both drugs aimed to fully eliminate residual CSC after 
chemotherapy should not be discarded. We suggest that binding of both antibodies to 
their targets could activate the complement system and would facilitate contact of 
opsonized tumor cells and molecules with granulocytes, macrophages and natural killer 
cells through the different FcγR displayed on their membranes thus increasing 
phagocytosis and promoting destruction of tumor cells through cell-to-cell contact 
mechanisms. A progressive increase of the proinflammatory environment around the 
tumor would completely activate more dendritic cells and other antigen-presenting 
cells, rendering them immunogenic and thus facilitating tumor antigen presentation to 
lymphocytes. This would progressively transform the immunosuppressive 
environment (tolerance) into a complete Th1 environment characterized by a 
significant increase of cellular immunity necessary for a complete tumor removal, 
including CSC. A decrease of the function and/or number of regulatory T cells (Treg) as 
a result of a dominant proinflammatory environment might also contribute to this 
positive response against the tumor. 
We recommend future research to be done with these two drugs in this type of 
difficult clinical situations. 
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Fig. 1. MRI March 2007. Initial diagnosis. 
 
 
 
Fig. 2. MRI September 2008. 
 
 
 
Fig. 3. MRI July 2009. 
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Fig. 4. MRI February 2010. 
 
 
 
Fig. 5. MRI at relapse. February 2011. 
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